Reliable and Easy-To-Use Liquid Chromatography-Tandem Mass Spectrometry Assay for Quantification of Olorofim (F901318), a Novel Antifungal Drug, in Human Plasma and Serum. [PDF]
Antimicrob Agents Chemother, 2018 A fast and easy-to-use liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for the determination and quantification of a novel antifungal drug, olorofim (F901318), a member of the novel class of orotomides, in human plasma and serum was developed and validated.
Müller C +6 more
europepmc +4 more sources
F901318 represents a novel class of antifungal drug that inhibits dihydroorotate dehydrogenase. [PDF]
Proc Natl Acad Sci U S A, 2016 Significance New antifungal drugs that act via novel mechanisms are urgently needed to combat the high mortality of invasive fungal disease and the emergence of resistance to existing therapies. We describe the discovery, structure, activity, and mechanism of action of F901318, a new antifungal agent. A member of a novel class of antifungals,
Oliver JD +13 more
europepmc +5 more sources
Efficacy of Olorofim (F901318) against Aspergillus fumigatus, A. nidulans, and A. tanneri in Murine Models of Profound Neutropenia and Chronic Granulomatous Disease. [PDF]
Antimicrob Agents Chemother, 2019 The emergence of azole resistance in Aspergillus fumigatus as well as an increasing frequency of multiresistant cryptic Aspergillus spp. necessitates exploration of new classes of antifungals.
Seyedmousavi S +5 more
europepmc +4 more sources
Superbugs or multidrug resistant microbes: A new threat to the society. [PDF]
Health Sci Rep, 2023 Health Science Reports, Volume 6, Issue 8, August 2023.
Painuli S, Semwal P, Sharma R, Akash S.
europepmc +2 more sources
Journal of Fungi, 2021 Olorofim is a novel antifungal drug that belongs to the orotomide drug class which inhibits fungal dihydroorotate dehydrogenase (DHODH), thus halting pyrimidine biosynthesis and ultimately DNA synthesis, cell growth and division. It is being developed at
Ourania Georgacopoulos +6 more
doaj +1 more source
Invasive pulmonary aspergillosis in the intensive care unit: current challenges and best practices
APMIS, Volume 131, Issue 11, Page 654-667, November 2023., 2023 The prevalence of invasive pulmonary aspergillosis (IPA) is growing in critically ill patients in the intensive care unit (ICU). It is increasingly recognized in immunocompetent hosts and immunocompromised ones. IPA frequently complicates both severe influenza and severe coronavirus disease 2019 (COVID‐19) infection.
Sarah Gaffney +4 more
wiley +1 more source
Internal Medicine Journal, Volume 53, Issue 8, Page 1489-1491, August 2023., 2023 Abstract Scedosporium and Lomentospora species are environmental moulds that are virulent in immunocompromised hosts and rarely cause bloodstream infection (BSI). Patients with Scedosporium and Lomentospora species BSI were identified by the state public laboratory service in Queensland, Australia, over a 20‐year period.
Adam G. Stewart +5 more
wiley +1 more source
EUCAST Determination of Olorofim (F901318) Susceptibility of Mold Species, Method Validation, and MICs [PDF]
Antimicrobial Agents and Chemotherapy, 2018 ABSTRACT Olorofim is a novel antifungal agent with in vitro activity against Aspergillus and some other molds. Here, we addressed technical aspects for EUCAST olorofim testing and generated contemporary MIC data.
Jørgensen, Karin Meinike +3 more
openaire +3 more sources
Invasive aspergillosis in liver transplant recipients
Transplant Infectious Disease, Volume 25, Issue 3, June 2023., 2023 Abbreviations: Ciclos, cyclosporine; CNS, central nervous system; IA, invasive aspergillosis; ICU, intensive care unit; IS, immunosuppression; MELD, model for end‐stage liver disease; RBC, red blood cell; Tac, tacrolimus. aMultivariate analysis. *For invasive fungal infection. **For solid organ transplant.
Cléa Melenotte +11 more
wiley +1 more source
Dihydroorotate dehydrogenase inhibitor F901318 has potent in vitro activity against Scedosporium species and Lomentospora prolificans [PDF]
Journal of Antimicrobial Chemotherapy, 2017 Scedosporium species and Lomentospora prolificans are increasing causes of invasive infections in immunocompromised hosts and many isolates are resistant to available antifungals. Our objective was to assess the in vitro potency of F901318, a member of the orotomide class of antifungals, against Scedosporium species and L.
Nathan P, Wiederhold +2 more
openaire +2 more sources